Literature DB >> 10440160

Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention.

M Rabah1, D Mason, D W Muller, R Hundley, A D Kugelmass, B Weiner, L Cannon, W W O'Neill, R D Safian.   

Abstract

OBJECTIVES: The purpose of this study was to determine the incidence of bleeding, vascular, and ischemic complications using three different heparin regimens after successful intervention.
BACKGROUND: The ideal dose and duration of heparin infusion after successful coronary intervention is unknown.
METHODS: Patients were randomized to one of three heparin strategies after coronary intervention: Group 1 (n = 157 patients) received prolonged (12 to 24 h) heparin infusion followed by sheath removal; Group 2 (n = 120 patients) underwent early removal of sheaths, followed by reinstitution of heparin infusion for 12 to 18 h; Group 3 (n = 137 patients) did not receive any further heparin after intervention with early sheath removal. The primary end point of the study was the combined incidence of in-hospital bleeding and vascular events. Secondary end points included in-hospital ischemic events, length of stay, cost and one-month outcome.
RESULTS: After successful coronary intervention, 414 patients were randomized. Unstable angina or postinfarction angina was present in 83% of patients before intervention. The combined incidence of bleeding and vascular events was 21% in Group 1, 14% in Group 2 and 8% in Group 3 (p = 0.01). The overall incidence of in-hospital ischemic complications was 2.2%; there were no differences between groups. Length of hospital stay was shorter (p = 0.033) and adjusted hospital cost was lower (p < 0.001) for Group 3. At 30 days, the incidence of delayed cardiac and vascular events was similar for all three groups.
CONCLUSIONS: Heparin infusion after successful coronary intervention is associated with more minor bleeding and vascular injury, prolonged length of stay and increased cost. In-hospital and one-month ischemic events rarely occur after successful intervention, irrespective of heparin use. Routine postprocedure heparin is not recommended, even in patients who present with unstable ischemic syndromes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440160     DOI: 10.1016/s0735-1097(99)00195-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  The economic burden of complications during percutaneous coronary intervention.

Authors:  Kurt M Jacobson; Kirsten Hall Long; Erin K McMurtry; James M Naessens; Charanjit S Rihal
Journal:  Qual Saf Health Care       Date:  2007-04

2.  The safety and efficacy of the Angio-Seal closure device in diagnostic and interventional neuroangiography setting: a single-center experience with 1,443 closures.

Authors:  Serdar Geyik; Kivilcim Yavuz; Ayca Akgoz; Osman Koc; Bora Peynircioglu; Barbaros Cil; Saruhan Cekirge; Isil Saatci
Journal:  Neuroradiology       Date:  2007-06-27       Impact factor: 2.804

3.  Safety and efficacy of Angio-Seal device for transfemoral neuroendovascular procedures: A systematic review and meta-analysis.

Authors:  Muhammed Amir Essibayi; Harry Cloft; Luis E Savastano; Waleed Brinjikji
Journal:  Interv Neuroradiol       Date:  2021-02-18       Impact factor: 1.764

4.  Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention.

Authors:  Jurriën M ten Berg; HW Thijs Plokker; Freek WA Verheugt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.